Connect with us

News

Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting

gbafNews28

Incyte (Nasdaq:INCY) announces that multiple abstracts, including data from its clinical development programs for ruxolitinib (Jakafi), pemigatinib and INCB50465 will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting 2018 in San Diego, California, from December 1-4, 2018.

Key data presented at ASH 2018 will include results from the pivotal REACH1 trial evaluating ruxolitinib in combination with corticosteroids for the treatment of patients with acute graft-versus-host disease (GVHD) who have had an inadequate response to corticosteroids, which have been accepted for oral presentation. Additionally, new data from the Phase 2 study evaluating INCB50465 in combination with ruxolitinib in patients with myelofibrosis (MF) and initial data from the Phase 2 fight-203 study evaluating pemigatinib in patients with myeloproliferative neoplasms (MPNs) with activating FGFR1 translocations have been accepted for oral presentation.

We are looking forward to highlighting our later-stage, targeted therapy portfolio at this years ASH Annual Meeting, said Steven Stein, M.D., Chief Medical Officer, Incyte. Specifically, we are pleased to present results from our REACH1 study, which formed the basis of our supplemental new drug application for ruxolitinib as a treatment for acute GVHD that is currently under Priority Review by the FDA, and new data from our INCB50465 and pemigatinib clinical development programs, which further underscore our leadership in MPNs.

Key abstract presentations include:

Ruxolitinib (Jakafi)

Oral Presentations

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase 2 Study (Abstract #354)

  • Sunday, December 2, 2018, 9:30-11:00 a.m., Manchester Grand Hyatt, Seaport Ballroom F, Oral Session 634, Myeloproliferative Syndromes: Clinical: Addressing Areas of Unmet Need in Prognostic Assessments and Therapy for MPNs

Results from REACH1, a Single-arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (Abstract #601)

  • Monday, December 3, 2018, 7:00-8:30 a.m., Manchester Grand Hyatt, Grand Hall A, Oral Session 722, Clinical Allogeneic Transplantation: Acute and Chronic GVHD

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase (Abstract #555)

  • Monday, December 3, 2018, 7:00-8:30 a.m., San Diego Convention Center, Ballroom 20A, Oral Session 614, Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Targeted Therapy in ALL: Immunotherapy and Beyond

RUXOPEG, a Multi-Center Bayesian Phase ½ Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasms-Associated Myelofibrosis* (Abstract #581)

  • Monday, December 3, 2018, 7:00-8:30 a.m., Manchester Grand Hyatt, Grand Hall D, Oral Session 634, Myeloproliferative Syndromes: Clinical: Interferon Therapy and Mutational Analysis in the MPNs

Poster Sessions

Updated Results from An Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study Of Ruxolitinib (Rux) In Patients (Pts) With Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant Or Intolerant And For Whom No Alternative Treatments Are Available (Abstract #1774)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster I

Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the REVEAL Study (Abstract #1770)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster I

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States (Abstract #1765)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster I

Impact of Myeloproliferative Neoplasms on Patients Employment and Income: Findings from the Living with MPN Survey (Abstract #2250)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 902, Health Services Research “ Malignant Diseases: Poster I

Elevated White Blood Cell levels and Thrombotic Events in Patients with Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data (Abstract #1758)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster I

Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the REVEAL Study (Abstract #2259)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 902, Health Services Research “ Malignant Diseases: Poster I

Long-term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) With Best Available Therapy (BAT) in Hydroxyurea (HU)-resistant/intolerant Patients (pts) With Polycythemia Vera (PV)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster I

Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera Without Splenomegaly: 156-Week Follow-Up From the Phase 3 RESPONSE-2 Study (Abstract #1754)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster I

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study (Abstract #4306)

  • Monday, December 3, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster III

Disease Characteristics of Minority Patient Populations with Polycythemia Vera: An Analysis from the REVEAL Study (Abstract #4735)

  • Monday, December 3, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 902, Health Services Research “ Malignant Diseases: Poster III

Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI) (Abstract #4312)

  • Monday, December 3, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 634, Myeloproliferative Syndromes: Clinical: Poster III

Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry (Abstract #4311)

  • Monday, December 3, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 634: Myeloproliferative Syndromes: Clinical: Poster III

INCB50465 (PI3Kδ)

Oral Presentation

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (Abstract #353)

  • Sunday, December 2, 2018, 9:30-11:00 a.m., Manchester Grand Hyatt, Seaport Ballroom F, Oral Session 634, Myeloproliferative Syndromes: Clinical: Addressing Areas of Unmet Need in Prognostic Assessments and Therapy for MPNs

Poster Session

Cell-of-Origin Subtype Prediction of Diffuse Large B-cell Lymphoma Using Gene Expression and Proteomic Data (Abstract #1712)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 627, Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)Results from Retrospective/Observational Studies: Poster I

Pemigatinib (INCB054828)

Oral Presentation

Interim Results from fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1) (Abstract #690)

  • Monday, December 3, 2018, 10:30-12:00 p.m., Manchester Grand Hyatt, Grand Hall A, Oral Session 634, Myeloproliferative Syndromes: Clinical: Emerging Therapies and Prognostic Scoring in Myelofibrosis and Other MPNs

Itacitinib

Plasma Biomarker Association with Response in Acute GVHD Subjects Treated With the Combination of Itacitinib and Corticosteroids in a Phase 1 Clinical Trial (Abstract #4559)

  • Monday, December 3, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 722, Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III

Ponatinib

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real World Clinical Practice “ Data from a Belgian Registry (Abstract #1744)

  • Saturday, December 1, 2018, 6:15-8:15 p.m., San Diego Convention Center, Hall GH, Poster Session 632, Chronic Myeloid Leukemia: Therapy: Poster I

Preclinical

The Persistent Survival of MPN Cells to JAK2 Inhibition is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies (Abstract #3064)

  • Sunday, December 2, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 635, Myeloproliferative Syndromes: Basic Science: Poster II

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-versus-Leukemia (GVL), Enhances Survival and is Highly Efficacious in a MHC-mismatched Mouse Model of Acute GvHD (Abstract #4522)

  • Monday, December 3, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 701, Experimental Transplantation: Basic Biology, Pre-Clinical Models Poster III

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-mismatched Mouse Model of Acute GvHD (Abstract 4523)

  • Monday, December 3, 2018, 6:00-8:00 p.m., San Diego Convention Center, Hall GH, Poster Session 701, Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster III

Full session details and data presentation listings for ASH 2018 can be found at: https://ash.confex.com/ash/2018/webprogram/start.html.

About Jakafi(ruxolitinib)

Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration for treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post“polycythemia vera MF, and post“essential thrombocythemia MF.

Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi (ruxolitinib) outside the United States. Jakafi is a registered trademark of Incyte Corporation. Jakavi is a registered trademark of Novartis AG in countries outside the United States. Ruxolitinib is also being evaluated in patients with acute and chronic GVHD who have an inadequate response to corticosteroids in the REACH2 and REACH3 clinical studies, respectively. It is expected that these two pivotal studies will complete in 2019, and could support additional regulatory submissions, in the U.S. by Incyte and ex-U.S. by Novartis, in 2020.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in Cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB), or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi, is available at www.jakafi.com.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Companys website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Companys development pipeline and its presentation plans for the upcoming ASH annual meeting, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Companys development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2018. Incyte disclaims any intent or obligation to update these forward-looking statements.

* Ex-U.S. Investigator Initiated Trials (IITs) are funded by Novartis.

Incyte Contacts
Media
Catalina Loveman
+1
302 498 6171
[email protected]
or
Investors
Michael
Booth, DPhil
+1 302 498 5914
[email protected]

News

Shanxi Shows Its New Charm of Cultural and Tourism Integration at China International Travel Mart 2020

gbafNews28

HONG KONG SAR – Media OutReach – 16 November 2020 – The China International Travel Mart 2020 (CITM 2020), co-sponsored by the Ministry of Culture and Tourism, Civil Aviation Administration of China, and the Shanghai Municipal People’s Government, will kick off at the Shanghai New International Expo Center from November 16th to 18th. With the theme of “Ancient Civilization of China · Beautiful Scenery of Shanxi”, Culture and Tourism Department of Shanxi Province will fully display Shanxi’s rich cultural tourism resources and products, such as “three world heritages” and three tourism sectors which are “the Yellow River, the Great Wall, and the Taihang Mountains”, showing its unique charm to the world.

 

[View Image]

Shanxi gets its name for being located in the west of Taihang Mountains. Its unique natural geographical conditions gestate magnificent scenery of Shanxi. The Yellow River ranked as the second-longest river in China, flows through 4 cities and 19 counties in Shanxi Province, forming the Hukou Waterfall, Qiankun Bay, Laoniu Bay, and other spectacular scenery. The beautiful landscape along the Taihang Mountains, represented by Hengshan Mountain, Taihang Grand Canyon, and Mount Wangmang, makes its four seasons as beautiful as paintings.


Shanxi Province, known as one of the cradles of Chinese civilization and one of the major provinces of Chinese culture, has left us numerous scenic spots, historical sites, and cultural treasures in the long history of thousands of years. The stories of Yao, Shun and Yu and their historical sites and remains have proven that it was the first place called “China”. Mount Wutai, the holy land of Buddhism, Pingyao Ancient City, and the Yungang Grottoes, one of the greatest ancient stone carving art treasure houses, are World Heritage Sites in Shanxi. The Great Wall, as the most recognizable cultural symbol of China, stretches 8,851 km (5500.3 mi), with 3,500 km (2175 mi) of that run across Shanxi Province. What’s more, intangible cultural heritages and food feasts throughout Shanxi make its cultural tourism brand image richer and livelier.


We do believe that the Culture and Tourism Department of Shanxi Province will bring Shanxi’s ancient Chinese civilizations and beautiful scenery to people from home and abroad with impressive results at the mart.

Continue Reading

News

Far East Hospitality announces local and regional expansion plans

gbafNews28

  • Venturing into new business segment with the addition of Oasia Resort Sentosa on Sentosa Island
  • Introducing a second Village hotel in Japan, and the first Quincy expansion in Australia 

SINGAPORE – Media OutReach – 17 November 2020 – Far East Hospitality, one of the leading operators of hotels and serviced residences, today announced that it will forge ahead with its local and regional expansion plans with three properties — Oasia Resort Sentosa, Far East Village Hotel Yokohama, and Quincy Hotel Melbourne.

Oasia makes a splash into Sentosa Island

[View Image]

A rendering of Oasia Resort Sentosa

Slated for opening in the second quarter of 2021, Oasia Resort Sentosa will be the fourth property on Sentosa island managed by Far East Hospitality. The homegrown company has signed a Hotel Management Agreement (HMA) with Far East Organization. Under the agreement, Far East Hospitality will be responsible for the hotel’s operations, and sales and marketing functions. This property also marks Far East Hospitality’s first foray into the resort and spa category.

 

“The progression into the resort and spa field is both a natural and calculated move,” said Arthur Kiong, Chief Executive of Far East Hospitality. “Each of our properties on Sentosa cater to different demographics. Village Hotel Sentosa for urban explorers and families. The Outpost Hotel for young couples who prefer exclusivity, and The Barracks Hotel for those who enjoy old world charm of the building’s architecture and service offerings. With Oasia Resort Sentosa, which targets the wellness conscious, it completes our suite of offerings on the island.”

The 191-key property consists of Suites, Wellness Premier Rooms, and Deluxe Rooms. Guests will have the opportunity to experience a wellness lifestyle encompassing not just a spa treatment, but healthy eating, fitness routines, mind-body practices, as well as connecting with nature. Wellness journals, self-care checklists, and access to a collection of guided meditation audio are amongst the many items that are made available for guests during their stay.

A second hotel in Japan

 

Four months after opening Far East Village Hotel Ariake — Far East Hospitality’s first venture into Japan, the company is expanding further with a management contract for a second Village property in Yokohama. Far East Village Hotel Yokohama is set to open in the second quarter of 2021. The 277-key property will be managed by Far East Hospitality under a HMA with Far East Organization.

Situated in the heart of downtown Yokohama, the property targets business travellers. It is a five-minute drive to the central business district and a three-minute walk to Sakuragicho and Kannai stations. Guests will also be able to Eat, Play, and Explore like a local at cultural enclaves such as Chinatown and the Red Brick Warehouse, and attractions such as the Cup Noodle Museum and Cosmoworld.

“Tourism in Japan has picked up gradually since the easing of travel curbs and the resumption of reciprocal ‘green lanes’ for business and official travel. We are also hopeful that launching the property will also give us the opportunity to capture the domestic market,” said Mr Kiong.

 

Quincy debuts in Australia, Melbourne

 

Quincy Melbourne is set to open in Q1 2021

From thoughtful spatial design to playful interiors and wondrous experiences — these are some of the finer things that guests can expect when Quincy Hotel Melbourne opens in the first quarter of 2021. The HMA is signed with InterGlobe through Far East Hospitality’s joint venture company, Toga Far East Hotels in Australia, marking the Quincy brand’s first expansion abroad.

Quincy’s quirky and anticipatory approach to service fits into Melbourne’s upbeat and experiential city lifestyle. Located at the top of Flinders Lane — a vibrant street in Melbourne’s central business district — the hotel targets at social urbanites with a penchant for experiential travel and the finer things in life. Guests will be able to enjoy South East Asian cuisine at its signature restaurant as well as access to its club levels and lounge. The hotel also boasts a rooftop pool with views of Melbourne CBD and the nearby lifestyle precinct.

Additional quotes from HMA partners can be found in ANNEX A.

ANNEX A: Quote sheet

 

Far East Hospitality is a 70-30 joint venture between Far East Orchard Limited and The Straits Trading Company Limited.

Commenting on the expansion plans, Far East Orchard’s Group Chief Executive Officer, Alan Tang said, “Hospitality business has been the core contributor to Far East Orchard’s earnings, and it is a vital part of our strategy to build a lodging platform and grow recurring income. Most recently, we crossed a significant milestone with the opening of our 100th hotel — Adina Melbourne Southbank, managed by Toga Far East Hotels. Through Far East Hospitality, we intend to continue growing our recurring income base with HMAs in key cities across the Asia-Pacific region; cities with strong long term fundamentals for the tourism industry, domestic travel and other demand drivers.”

On bringing the Quincy brand to Melbourne, Toga Far East Hotels’ Chief Executive Officer, Antony Ritch said, “We are thrilled to introduce Far East Hospitality’s colourful Quincy brand into Australia early next year. With Quincy we are bringing the sights, sounds and most importantly flavours of South East Asia to Australia.

About Far East Hospitality

Far East Hospitality Holdings Pte Ltd (Far East Hospitality) is an international hospitality owner and operator with a diverse portfolio of 9 unique and complementary brands of hotels, serviced residences and apartment hotels, including Oasia, Quincy, Rendezvous, Village, Far East Collection, Adina Hotels, Vibe Hotels, Travelodge Hotels and TFE Hotels Collection.

Far East Hospitality owns more than 10 hospitality assets and operates a combined portfolio of more than  16,500 rooms under its management across 100 hotels and serviced residences in eight countries — Australia, Denmark, Germany, Hungary, Japan, Malaysia, New Zealand and Singapore, with more in its development pipeline. In 2020, the group ranked amongst the top 100 hotel companies by HotelsMag.

Far East Hospitality is a 70-30 joint venture formed in 2013 between Far East Orchard Limited (a listed company under Far East Organization) and The Straits Trading Company Limited. In the same year, Far East Hospitality, through its wholly-owned subsidiary Far East Hospitality Investments (Australia) Pte Ltd, completed a 50-50 joint venture with Australia’s Toga Group to form Toga Far East Hotels (TFE Hotels).

For more information, visit https://www.FarEastHospitality.com/.

Continue Reading

News

va-Q-tec signs extensive heads of terms agreement on provision of thermal containers for global CoVid-19 vaccine distribution with top international pharmaceuticals producer

gbafNews28

  • One of the largest pharmaceutical manufacturers secures capacities from va-Q-tec for thermal containers for international, temperature-controlled vaccine distribution.
  • Order to be executed from first quarter of 2021 subject to expected vaccine approval.
  • va-Q-tec is thereby probably the world’s first provider of temperature-controlled thermal containers with a confirmed partnership for global logistics for CoVid-19 vaccines in this volume.
  • Further talks between va-Q-tec and other vaccine manufacturers being held in parallel.
  • va-Q-tec’s high-tech passive transport containers provide key technology required for temperature-controlled vaccine distribution, reliably maintaining constant temperatures in various ranges between -70 °C and 25 °C — including over several days.

 

WÜRZBURG, GERMANY – Media OutReach – 19 November 2020 – va-Q-tec, a pioneer of highly efficient thermal containers and boxes for temperature-controlled logistics, announces the successful conclusion of a comprehensive agreement with one of the largest pharmaceutical manufacturers for the international distribution of a coronavirus vaccine. This probably makes the company the first in the thermal container sector to agree a confirmed partnership for large-scale global thermal transports in connection with the CoVod- 19 vaccine. va-Q-tec is aware of its great responsibility: in addition to the development and validation of the vaccine, which is currently taking place under intense pressure, secure worldwide distribution is considered a mammoth logistical and technical task. As part of the agreement, the customer is securing capacities for international, temperature-controlled vaccine distribution. Such capacities could become increasingly scarce, according to sector information.

 

As part of the related heads of terms agreement, it has been arranged with the partner that, subject to approval, the worldwide, large-volume distribution of its vaccines deploying va-Q-tec’s innovative transport solutions is to start in the first quarter of 2021. The order volume comprises several thousand high-performance transport containers. The parties intend to conclude a final agreement soon concerning the total volume of the partnership based on the heads of terms agreement. The approval of the active substance is a prerequisite for this agreement. At this stage, it is assumed that such approval will be granted.

 

The investments made so far realized in the expansion of va-Q-tec’s fleet create the necessary capacities for this order, as well as for possible follow-up orders. The fleet will be expanded significantly further over the coming months. As a consequence, the German company operates the world’s largest fleet of thermal containers, whose interiors maintain even low temperature ranges at a constant level of -20 °C and below over a period of several days. For this reason, va-Q-tec is in an ideal position to provide secure and reliable logistics for the valuable vaccine in the context of such a large-scale request, and has already many years of experience with international transports below -60 °C.

The company offers a unique, coordinated portfolio of different high-performance thermal container and box solutions that enable it to handle such a complex, international logistic task. In addition to large-volume international shipments, all types of transport can be realized utilizing the same proven technology, including on the last mile to the end customer or patient.

 

The company offers a fleet of several 1000 high-tech rental containers within its network of 40 international stations. Reliable availability for increased global demand or transportation to countries with challenging logistics infrastructures is also ensured by a container variant that is available for purchase: with the va-Q-pal SI, a cost-efficient and sustainable pallet container has been specially developed that reliably maintains required temperatures for many days. It can be re-qualified several times, enabling it to be reutilized at its original performance level. For this purpose, before being reutilized, the entire insulation can be checked easily for full functionality.

 

Above and beyond the agreement that has been reached, va-Q-tec is in advanced negotiations aimed at comparable partnerships with further international vaccine manufacturers. Coronavirus vaccines are already being moved in the company’s thermal transport solutions, some of them are being pre- produced and distributed in large volumes on a pre-approval basis in order to supply the population with the vaccines immediately after official approval. In many such cases, little data is available on stability during transport and storage. Consequently, va-Q-tec transports the same coronavirus vaccines on an intercontinental basis at -70 °C, as well as on a local microdistribution basis at +2 to 8°C. This is in the same boxes and containers easily possible thanks to the company’s unique technology.

 

Dr. Joachim Kuhn, CEO and founder of va-Q-tec, adds: “First-class scientists have developed a vaccine within a very short time, and we are now helping to distribute the vaccine with our secure transport solutions. The present agreement is the most extensive in our twenty-year corporate history, and perhaps one of the most extensive in the sector ever. With our unique technology, our broad portfolio and our years of experience with low and very low temperatures, we can optimally support the global distribution of the coronavirus vaccine. Thanks to the extensive expansion of our container and box fleet as well as our worldwide network, we offer ideal prerequisites for tackling this enormous logistics challenge. We are proud to be able to make our contribution to the major common goal of the global battle against the CoVid-19 pandemic.”

About va-Q-tec

va-Q-tec is a pioneer in highly efficient products and solutions in the area of thermal insulation and TempChain logistics. The company develops, produces and markets highly efficient and consequently thin vacuum insulation panels (VIPs) as well as phase change materials (PCMs) for reliable and energy-efficient temperature controlling. In addition, va-Q-tec produces passive thermal packaging systems (containers and boxes) through optimally integrating VIPs and PCMs, which can maintain constant temperatures, depending on type, for up to 200 hours without external energy input. In order to implement temperature- sensitive logistics chains, va-Q-tec — within a global partner network — operates a fleet of rental containers and boxes meeting demanding thermal protection standards. Along with Healthcare & Logistics as the main market, va-Q-tec addresses the following further markets: Appliances & Food, Technics & Industry, Building, and Mobility. The high-growth company, which was founded in 2001, is based in Würzburg, Germany.

Further information: www.va-q-tec.com

Twitter: [View Image]@vaQtec

LinkedIn: linkedin.com/company/va-Q-tec

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News2 hours ago

Shanxi Shows Its New Charm of Cultural and Tourism Integration at China International Travel Mart 2020

HONG KONG SAR – Media OutReach – 16 November 2020 – The China International Travel Mart 2020 (CITM 2020), co-sponsored by the Ministry...

gbafNews28 gbafNews28
News2 hours ago

Genesis and Symphony Partner to Accelerate Digitisation and Connectivity for The Global Financial Markets Community

HONG KONG SAR – Media OutReach – 19 November 2020 – Genesis, the Low-Code Application Platform (LCAP) and Symphony Communication Services, LLC (hereafter...

gbafNews28 gbafNews28
News2 hours ago

80+ social innovators from around the world to shape the New Normal online at the 13th Social Enterprise Summit

HONG KONG SAR – Media OutReach – 19 November 2020 – The 13th Social Enterprise Summit kicked off today in an online format....

gbafNews28 gbafNews28
News2 hours ago

CIFI issued US$350 million senior notes at a coupon rate of 5.25% due 2026

Redemption of US$420 million senior notes and perpetual bonds reduce average financing costs effectively and optimize debt structure   HONG...

gbafNews28 gbafNews28
News2 hours ago

James Dyson Award 2020: At-home breast cancer screening device and a novel new material to generate renewable electricity BOTH win global prize

HONG KONG SAR – Media OutReach – 19 November 2020 – 2020 was a record-breaking year for the James Dyson Award, which has...

gbafNews28 gbafNews28
News2 hours ago

Beyond Meat Introduces Brand New Beyond Pork™ Product in China

The plant-based minced pork is Beyond Meat’s latest cutting-edge innovation and the company’s first product developed specifically for the Chinese...

gbafNews28 gbafNews28
News2 hours ago

va-Q-tec signs extensive heads of terms agreement on provision of thermal containers for global CoVid-19 vaccine distribution with top international pharmaceuticals producer

One of the largest pharmaceutical manufacturers secures capacities from va-Q-tec for thermal containers for international, temperature-controlled vaccine distribution. Order to...

gbafNews28 gbafNews28
News2 hours ago

Inaugural True Colors Film Festival 2020 – One World, One Family

SINGAPORE – Media OutReach – 19 November 2020 – True Colors Film Festival (TCFF) runs online from 3 to 12 December 2020. Offering 30 award-winning...

gbafNews28 gbafNews28
News2 hours ago

NEW: True Colors Film Festival 2020 – About “One World, One Family”

SINGAPORE – Media OutReach – 19 November 2020 – True Colors Film Festival (TCFF) runs online from 3 to 12 December 2020. Offering 30 award-winning...

gbafNews28 gbafNews28
News2 hours ago

True Colors Film Festival 2020 – Includes Yasmin Ahmad’s final film, Talentime

SINGAPORE – Media OutReach – 19 November 2020 – True Colors Film Festival (TCFF) runs online from 3 to 12 December 2020. Offering 30 award-winning...